给药途径及剂型因素对两种晶型利福平药动学的影响-制药工程专业论文.docxVIP

administration of rifampicin suspension II, the main parameters: Tmax was 2.975 h, Cmax was 13.68 μg/mL, AUC0-t was 82.60 h*mg/mL. After rectal administration of rifampicin suspension II, the main parameters: Tmax was 4.025 h, Cmax was 8.950 μg/mL, AUC0-t was 52.54 h*mg/mL. (4) After oral administration of rifampicin capsule II, the main parameters: Tmax was 2.075 h, Cmax was 8.375 μg/mL, AUC0-t was 56.25 h*mg/mL. After rectal administration of rifampicin capsule II, the main parameters: Tmax was 4.125 h, Cmax was 7.425 μg/mL, AUC0-t was 47.37 h*mg/mL. After oral administration of rifampicin, form II showed a higher bioavailability than form I. However, after rectal administration of two crystal forms of rifampicin, form I exhibited a higher bioavailability than form II. The bioavailability of rifampicin suspension was higher than capsule, which was not affected by delivery routes. KEY WORDS: Polymorphs, Rifampicin, Bioavailability, Dosage form, Delivery route 目 录 HYPERLINK \l _bookmark0 第一章 文献综述 1 HYPERLINK \l _bookmark1 1.1 利福平 1 HYPERLINK \l _bookmark2 1.1.1 利福平概述 1 HYPERLINK \l _bookmark3 1.1.2 利福平的晶型研究 1 HYPERLINK \l _bookmark4 1.1.3 利福平的剂型研究 3 HYPERLINK \l _bookmark5 1.2 药代动力学 4 HYPERLINK \l _bookmark6 1.2.1 晶型对药物体内药动学的影响 5 HYPERLINK \l _bookmark7 1.2.2 给药途径对多晶型药物药动学的影响 6 HYPERLINK \l _bookmark8 1.2.3 剂型对多晶型药物药动学的影响 7 HYPERLINK \l _bookmark9 1.2.4 其他因素对多晶型药物药动学的影响 7 HYPERLINK \l _bookmark10 1.3 多晶型利福平的体内药动学研究 8 HYPERLINK \l _bookmark11 1.4 课题立题依据 9 HYPERLINK \l _bookmark12 第二章 利福平的晶型研究 10 HYPERLINK \l _bookmark13 2.1 实验仪器与试剂 10 HYPERLINK \l _bookmark14 2.1.1 实验仪器 10 HYPERLINK \l _bookmark15 2.1.2 实验试剂 10 HYPERLINK \l _bookmark16 2.2 利福平的晶型研究 10 HYPERLINK \l _bookmark17 2.2.1 性状 10 HYPERLINK \l _bookmark18 2.2.2 粉末 X-射线衍射分析(PXRD) 11 HYPERLINK \l _bookmark19 2.2.3 差示扫描量热分析(DSC) 11 HYPERLINK \l _bookmark20 2.2.4 扫描电镜分析（SEM） 11 HYPERLINK \l _bookmark21 2.3 结果与讨论 11 HYPERLINK \l _bookmark22 2.3.1 性状 11 HYPERLINK \l _bookmark23 2.3.2 粉末 X